Collaboration to be Led by Professor Eli Lewis, One of World’s Leading Alpha-1 Antitrypsin Researchers
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announced today a collaboration for advanced research on Alpha-1 Antitrypsin (AAT) with a focus on mechanism of action with BGN Technologies (BGN), the business arm of Ben-Gurion University (BGU). Professor Eli Lewis, Department of Clinical Biochemistry and Pharmacology at BGU, and one of the world’s foremost AAT investigators, will lead the collaboration.
This agreement follows previous successful collaborations between Kamada and Professor Lewis’ team, and is expected to provide the groundwork for further AAT research amongst the parties. As part of this most recent collaboration, BGN, through Professor Lewis, will provide various services to Kamada, including a thorough evaluation of AAT’s attributes, beyond its anti-protease characteristics, such as effectively interfering with inflammatory responses, immuno-modulatory effect and protection from cell death. Furthermore, the planned research studies will serve as a scientifically and regulatory well-founded background to compare recombinant human AAT products that are developed as part of Kamada’s potential future pipeline.
“Professor Lewis is one of the world’s leading experts in AAT research, and we are excited to continue collaborating with him and BGN. During the course of his career, Professor Lewis has investigated the effect of AAT on immune tolerance, T-regulatory cells, beta-cell regeneration, auto-immune diseases, and immunological disorders,” said Amir London, Kamada’s Chief Executive Officer. “These studies will help us evaluate the potential of our AAT for the treatment of various other indications outside of AAT-Deficiency, Graft-vs-Host Disease, Lung Transplantation, and Type-1 Diabetes.”
“Kamada is a clear leader in AAT-based product development, and we look forward to expanding our long-standing relationship with the company through this collaboration,” said Professor Lewis. “I believe this work will lay the foundation for future additional AAT-related research with Kamada. AAT has significant potential in the treatment of many debilitating medical conditions, and we are excited to further our understanding of this important protein.”
Click here to see the full story.